BTW - to address a point made at the top of this thread (that ppl on this board have gotten relief from everything to hiccups to athletes foot (made up examples)), this is a board of true believers. I have zero doubt that placebo effect runs much higher in true believers. Great for them, but I wouldn’t expect it to replicate in non-believers.
In the context of the thread, I think that's a petty/ insulting slight against a broad swath of posters. Personally I know of just one patient, who is on Vascepa because of a past stroke, and who is surprised (even shocked, because nothing else had worked) to have lost 9lbs (153 down to 144) with increased mobility/activity, after just 2-3 months of use.
The poster you are replying to suggests that the post-approval label and marketing will likely increase compliance due to the FDA-confirmed claims of CV outcomes benefit. But you - expect compliance to go down as a higher percentage become non-true-believers - without any explanation why that might happen.
You also dismiss the poster's argument on the basis that - the uptake growth over last year has been much higher than previous yrs - as a result of MACE results. OK, the MACE results have been marketed in brochures to the docs - but NOT to the patients. Compliance is not a doc issue, its a patient issue - and they will now get the updated label with every Vascepa bottle, showing the approved CV outcomes benefit. So the poster's position that the label will be compelling to patients is perfectly reasonable.
Market Data 
Markets 
AI
